Cosciens BiopharmaCSCIF -5.24%62 EBITDA Margin % is 10.81% as of Mar. 2026, which is 223% above its 10-year median of 3.35. GuruFocus rates CSCIF with a GF Score™ of 62/100 and a GF Value™ of $2.35 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 945 Biotechnology companies, Cosciens Biopharma ranks worse than 50.26% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cosciens Biopharma's EBITDA for the
three
months ended in Mar. 2026 was $0.20 Mil. Cosciens Biopharma's Revenue for the
three
months ended in Mar. 2026 was $1.89 Mil. Therefore, Cosciens Biopharma's EBITDA margin for the quarter that ended in Mar. 2026 was 10.81%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cosciens Biopharma EBITDA Margin % Related Terms
Cosciens Biopharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSCIF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Cosciens Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma (CSCIF) has a EBITDA Margin % of 10.81% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cosciens Biopharma and its competitors. This is 223% above median its historical median of 3.35. According to the industry distribution chart, Cosciens Biopharma ranks #475 out of 945 companies in the Biotechnology industry, placing it in the top 50.3%.
Is Cosciens Biopharma's EBITDA Margin % too high?
Cosciens Biopharma's current EBITDA Margin % of 10.81% is 223% above median its 10-year median of 3.35. Based on the distribution chart, Cosciens Biopharma ranks #475 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cosciens Biopharma has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #475 out of 945 companies for EBITDA Margin %. This places Cosciens Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current EBITDA Margin % is 10.81%, which is 223% above median its own 10-year median of 3.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.35, compared to a current price of $1.99 — trading 15.3% below its estimated fair value. The current EBITDA Margin % is 10.81%, which is 223% above median its 10-year median of 3.35. Cosciens Biopharma's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current EBITDA Margin % is 10.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $1.99 is trading 15.3% below its estimated GF Value™ of $2.35.
GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.
Key valuation signals for CSCIF:
EBITDA Margin %: 10.81% (223% above median its 10-year median of 3.35)
GF Value™: $2.35 vs. price of $1.99 (15.3% below fair value)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
62GF Score
Get the complete analysis for CSCIF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
